Who is keeping the price down ., page-28

Hi Kogarah

this is the rest of the article


Dimerix (ASXXB)
Dimerix is conducting three phase III studies and two of them are due before 2021 is out.

The pair due this year both involve Dimerix’s chemokine receptor (CCR2) blocker DMX-200 in large-scale assessments of COVID-19 respiratory treatments but are with different research.

The good news for shareholders is whatever the outcome, Dimerix will not be on the hook for the costs because these were initiated by the investigators.

One of these studies resulted in a $1 million grant from The Australian government’s Medical Research Future Fund.

And while regulatory approval is typically another complex step for drugmakers, Dimerix’s path could be easier with regulators typically quick to grant emergency use authorisation to any drug or treatment that can fight the pandemic.

Dimerix’s other Phase III clinical trial – due next year – is against a rare kidney disease known as FSGS (focal segmental glomerulosclerosis


Telix Pharmaceuticals (ASX:TLX)
This $1.2 billion ASX biotech stock has a Phase III trial evaluating TLX250-CDx as a diagnostic agent targeting clear cell Renal Cell Carcinoma (ccRCC) in 252 patients across Australia and North America.

ccRCC is a type of kidney cancer which is the most common type in adults.

Telix anticipates completing patient enrolment in the middle of the year and with the study running 42 days for each participants it hopes to have the trial data-set available in “late 2021”.

The company has also pencilled in that time to schedule a meeting with the FDA regaring a Biological License Application.

Telix has also begun a Phase III study for another drug, TLX591, against prostate cancer. The study has begun in Australia but will expand to the US, Europe and possibly Asia in the next nine months

MGC Pharmaceuticals (ASX:MXC)
This cannabis focused company is also fighting COVID-19, conducting a Phase III clinical trial across Israel and Brazil with its anti-inflammatory medicine CimetrA.

MGC received ethics approval back in March and hopes to have results available in the fourth quarter of this year although interim results are anticipated to be available in August.